A brief introduction to the drug Vorinostat

Vorinostat (Vorinostat) is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or relapsing disease after two systemic therapies. The recommended dose of vorinostat is 400 mg once daily with food. Treatment can be continued as long as there is no evidence of disease progression or unacceptable toxicity. The most common drug-related adverse reactions can be divided into 4 comprehensive symptoms: Gastrointestinal symptoms (diarrhea, nausea, anorexia, weight loss, vomiting, constipation), systemic symptoms (fatigue, chills), hematological abnormalities (thrombocytopenia, anemia) and taste disorders (dysgeusia, dry mouth).